28 related articles for article (PubMed ID: 37737453)
1. RNF115 aggravates tumor progression through regulation of CDK10 degradation in thyroid carcinoma.
Zhu J; Guo L; Dai H; Zheng Z; Yan J; Liu J; Zhang S; Li X; Sun X; Zhao Q; Xu C
Cell Biol Toxicol; 2024 Feb; 40(1):14. PubMed ID: 38376606
[TBL] [Abstract][Full Text] [Related]
2. Raf/MEK/ERK Signaling Pathway Is Involved in the Inhibition of Glioma Cell Proliferation and Invasion in the Ketogenic Microenvironment.
Fan WT; Liu XF; Liang RC
Curr Med Sci; 2023 Aug; 43(4):759-767. PubMed ID: 37498407
[TBL] [Abstract][Full Text] [Related]
3. CDK10/cyclin M is a protein kinase that controls ETS2 degradation and is deficient in STAR syndrome.
Guen VJ; Gamble C; Flajolet M; Unger S; Thollet A; Ferandin Y; Superti-Furga A; Cohen PA; Meijer L; Colas P
Proc Natl Acad Sci U S A; 2013 Nov; 110(48):19525-30. PubMed ID: 24218572
[TBL] [Abstract][Full Text] [Related]
4. PPP1R14D promotes the proliferation, migration and invasion of lung adenocarcinoma via the PKCα/BRAF/MEK/ERK signaling pathway.
Cao H; Wang Z; Wang Y; Ye L; Li R; Xue Y; Li K; Di T; Li T; Fan Z; Liu Y; Guo J; Yao H; Ge C
Int J Oncol; 2022 Dec; 61(6):. PubMed ID: 36263632
[TBL] [Abstract][Full Text] [Related]
5. Identification of murine cdk10: association with Ets2 transcription factor and effects on the cell cycle.
Bagella L; Giacinti C; Simone C; Giordano A
J Cell Biochem; 2006 Oct; 99(3):978-85. PubMed ID: 16741970
[TBL] [Abstract][Full Text] [Related]
6. E26 Transformation-Specific Transcription Factor ETS2 as an Oncogene Promotes the Progression of Hypopharyngeal Cancer.
Liu X; Zhang C; Zhang Z; Zhang Z; Ji W; Cao S; Cai X; Lei D; Pan X
Cancer Biother Radiopharm; 2017 Nov; 32(9):327-334. PubMed ID: 29111780
[TBL] [Abstract][Full Text] [Related]
7. Cdk10, a Cdc2-related kinase, associates with the Ets2 transcription factor and modulates its transactivation activity.
Kasten M; Giordano A
Oncogene; 2001 Apr; 20(15):1832-8. PubMed ID: 11313931
[TBL] [Abstract][Full Text] [Related]
8. CDK10 suppresses metastasis of lung adenocarcinoma through inhibition of the ETS2/c-Raf/p-MEK/p-ERK signaling loop.
Zhang X; Zhao Y; Yiminniyaze R; Zhu N; Zhang Y; Wumaier G; Xia J; Dong L; Zhou D; Wang J; Li C; Zhang Y; Li S
Mol Carcinog; 2024 Jan; 63(1):61-74. PubMed ID: 37737453
[TBL] [Abstract][Full Text] [Related]
9. The awakening of the CDK10/Cyclin M protein kinase.
Guen VJ; Gamble C; Lees JA; Colas P
Oncotarget; 2017 Jul; 8(30):50174-50186. PubMed ID: 28178678
[TBL] [Abstract][Full Text] [Related]
10. Is the Canonical RAF/MEK/ERK Signaling Pathway a Therapeutic Target in SCLC?
Cristea S; Sage J
J Thorac Oncol; 2016 Aug; 11(8):1233-1241. PubMed ID: 27133774
[TBL] [Abstract][Full Text] [Related]
11. The Role of Activation of PI3K/AKT/mTOR and RAF/MEK/ERK Pathways in Aggressive Pituitary Adenomas-New Potential Therapeutic Approach-A Systematic Review.
Derwich A; Sykutera M; Bromińska B; Rubiś B; Ruchała M; Sawicka-Gutaj N
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446128
[TBL] [Abstract][Full Text] [Related]
12. RAF-MEK-ERK pathway in cancer evolution and treatment.
Ullah R; Yin Q; Snell AH; Wan L
Semin Cancer Biol; 2022 Oct; 85():123-154. PubMed ID: 33992782
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
